Silence Therapeutics Files Form 6-K

TL;DR

Silence Therapeutics filed a 6-K, standard reporting for foreign issuers.

AI Summary

Silence Therapeutics plc filed a Form 6-K on November 18, 2024, to report information for the month of November 2024. The filing is for a foreign private issuer and will be incorporated by reference into the company's registration statements.

Why It Matters

This filing indicates ongoing reporting requirements for Silence Therapeutics plc as a publicly traded foreign private issuer in the United States.

Risk Assessment

Risk Level: low — This is a routine SEC filing for a foreign private issuer, not indicating any specific new risks.

Key Numbers

• 001-39487 — SEC File Number (Identifies the company's filing with the SEC.)

Key Players & Entities

• Silence Therapeutics plc (company) — Registrant
• 001-39487 (company) — SEC File Number
• 20241118 (date) — Filing Date

FAQ

Filing Documents

• d828427d6k.htm (6-K) — 11KB
• d828427dex991.htm (EX-99.1) — 16KB
• g828427g1118221119597.jpg (GRAPHIC) — 3KB
• 0001193125-24-260987.txt ( ) — 32KB

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INCORPORATION BY REFERENCE This Report on Form 6-K (this Report) of Silence Therapeutics plc (the Company), excluding Exhibit 99.1 attached hereto, shall be deemed to be incorporated by reference into the Companys registration statement on Form F-3ASR (File No. 333-282779), the Companys registration statement on Form F-3 (File No. 333-279185), and the Companys registration statements on Form S-8 (File Nos. 333-248682 and 333-273576) and to be a part thereof from the date on which this Report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit 99.1 to this Report is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K Press Release On November 18, 2024, the Company issued a press release announcing the presentation of end-of-treatment data from the Companys Phase 2 clinical trial of zerlasiran at the 2024 American Heart Association Annual Meeting. A copy of the press release is fumished as Exhibit 99.1 to this Report. EXHIBIT INDEX Exhibit No. Description 99.1 Press release, dated November 18, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SILENCE THERAPEUTICS PLC Date: November 18, 2024 By: /s/ Craig Tooman Craig Tooman President and Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR